Context Therapeutics
CNTX
79 hedge funds and large institutions have $34.8M invested in Context Therapeutics in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 15 closing their positions.
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
34% more funds holding
Funds holding: 59 → 79 (+20)
12.37% less ownership
Funds ownership: 80.73% → 68.36% (-12%)
82% less capital invested
Capital invested by funds: $194M → $34.8M (-$160M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.8M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.49M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.39M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.05M |
| 5 |
Renaissance Technologies
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$19M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.86M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.2M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$4.46M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$4.37M |
CNTX Hedge Fund Activity: Q2 2026 in Review
79 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2026, worth a combined $34.8M — down 82% from $194M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CNTX positions and 15 closed out — a net gain of 21 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $10.8M. The largest seller was MPM BioImpact, cutting an estimated $19M.
- 79 institutional investors held Context Therapeutics (CNTX) as of Q2 2026, up from 59 in Q1 2026.
- Funds reported $34.8M of Context Therapeutics stock for Q2 2026, down 82% quarter-over-quarter.
- 36 funds opened new Context Therapeutics positions in Q2 2026 and 15 closed out, a net change of +21 holders.
- The largest Context Therapeutics buyer in Q2 2026 was BlackRock, an estimated $10.8M added.
- The largest Context Therapeutics seller in Q2 2026 was MPM BioImpact, an estimated $19M sold.
Based on aggregated 13F filings for Q2 2026.